Stay updated with breaking news from Lineage Cell. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Lineage Cell Therapeutics (NYSEAMERICAN:LCTX – Get Free Report)‘s stock had its “buy” rating reissued by equities researchers at HC Wainwright in a research note issued on Tuesday, Benzinga reports. They currently have a $7.00 price objective on the stock. Separately, Cantor Fitzgerald reiterated an “overweight” rating and issued a $6.00 price target on shares of […]
Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX – Get Free Report) saw a significant increase in short interest in the month of June. As of June 30th, there was short interest totalling 6,440,000 shares, an increase of 19.0% from the June 15th total of 5,410,000 shares. Based on an average daily volume of 715,600 shares, the short-interest […]
And Donald Trump files a countersuit against E. Jean Carroll.
Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX – Get Rating) – Equities research analysts at HC Wainwright raised their FY2027 earnings per share (EPS) estimates for Lineage Cell Therapeutics in a research note issued to investors on Friday, May 12th. HC Wainwright analyst J. Pantginis now expects that the company will post earnings of $0.00 per share […]
An allogeneic retinal pigment epithelial cell therapy may help slow disease progression in geographic atrophy secondary to age-related macular degeneration, according to a press release from Lineage Cell Therapeutics.